Soligenix, Inc. is a biotechnology company that focuses on the development and commercialization of products for treating rare diseases and addressing unmet medical needs.
Soligenix works on improving the lives of patients globally. Its leaders have many years of experience in the biopharmaceutical industry and expertise in developing rare disease therapies.
Soligenix specializes in developing orphan and unmet medical need indications that include preclinical, manufacturing, regulatory and clinical expertise. Soligenix is building SGX301 as a photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, SGX942, a novel innate defense regulator technology for the treatment of oral mucositis and SGX203, a proprietary formulations of oral beclomethasone 17, 21-dipropionate (BDP) for the prevention and treatment of gastrointestinal disorders that are characterized by severe inflammation including pediatric Crohn’s disease.
Soligenix offers public health solutions business segment that includes active development programs for RiVax®, its ricin toxin vaccine candidate, SGX943.
